VIR-7831 for the Early Treatment of COVID-19 in Outpatients
Status:
Completed
Trial end date:
2021-09-02
Target enrollment:
Participant gender:
Summary
This is a phase 2/3 study in which subjects with coronavirus disease 2019 (COVID-19) will
receive VIR-7831 or placebo and will be assessed for safety, tolerability, efficacy, and
pharmacokinetics.